{"id":46126,"date":"2023-09-01T07:00:00","date_gmt":"2023-09-01T07:00:00","guid":{"rendered":"http:\/\/2ab1d3ad31265ad8d2844d7bd9c2d2c5"},"modified":"2024-11-03T15:12:23","modified_gmt":"2024-11-03T15:12:23","slug":"fda-approves-pralsetinib-for-non-small-cell-lung-cancer-with-ret-gene-fusions","status":"publish","type":"post","link":"https:\/\/ogkologos.com\/en\/fda-approves-pralsetinib-for-non-small-cell-lung-cancer-with-ret-gene-fusions\/","title":{"rendered":"FDA Approves Pralsetinib for Non-Small Cell Lung Cancer with RET Gene Fusions"},"content":{"rendered":"<p>On 9 August 2023, the US Food and Drug Administration (FDA) granted regular approval to pralsetinib (Gavreto, Genentech, Inc.) for adult patients with metastatic rearranged during transfection (<em>RET<\/em>) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.<\/p>\n<p>Pralsetinib was previously granted accelerated approval for the NSCLC indication on 4 September 2020, based on initial overall response rate (ORR) and duration of response (DoR) in 114 patients enroled in the ARROW (NCT03037385), a multicentre, open-label, multi-cohort study. The conversion to regular approval was based on data from an additional 123 patients and 25 months of additional follow-up to assess durability of response.<\/p>\n<p>Full prescribing information for Gavreto is available <a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/213721s009lbl.pdf\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"external-link\">here<\/a>.<\/p>\n<p>Efficacy was demonstrated in a total of 237 patients with locally advanced or metastatic <em>RET <\/em>fusion-positive NSCLC. Patients received pralsetinib until disease progression or unacceptable toxicity.<\/p>\n<p>The primary efficacy measures were ORR and DoR as determined by a Blinded Independent Review Committee. Among 107 treatment-na\u00efve patients, ORR was 78% (95% confidence interval [CI] 68, 85) with a median DoR of 13.4 months (95% CI 9.4, 23.1). Among 130 patients previously treated with platinum-based chemotherapy, ORR was 63% (95% CI 54, 71) with a median DoR of 38.8 months (95% CI 14.8, not estimable).<\/p>\n<p>The most common adverse reactions (\u226525%) were musculoskeletal pain, constipation, hypertension, diarrhoea, fatigue, oedema, pyrexia, and cough.<\/p>\n<p>The recommended pralsetinib dose is 400 mg orally once daily. Pralsetinib is taken on an empty stomach (no food intake for at least 2 hours before and at least 1 hour after taking pralsetinib).<\/p>\n<p>This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA\u2019s assessment.<\/p>\n<p>This application was granted breakthrough designation and orphan drug designation.<\/p>\n<p>Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA\u2019s MedWatch Reporting System.<\/p>\n<p>For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact FDA\u2019s <a href=\"https:\/\/www.fda.gov\/about-fda\/fda-organization\/oncology-center-excellence\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"external-link\">Oncology Center of Excellence<\/a>&nbsp;<a href=\"https:\/\/www.fda.gov\/about-fda\/oncology-center-excellence\/project-facilitate\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"external-link\">Project Facilitate<\/a>.<\/p>\n<p><a href=\"https:\/\/www.esmo.org\/oncology-news\/fda-approves-pralsetinib-for-non-small-cell-lung-cancer-with-ret-gene-fusions\">Source<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>On 9 August 2023, the US Food and Drug Administration (FDA) granted regular approval to pralsetinib (Gavreto, Genentech, Inc.) for adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. Pralsetinib was previously granted accelerated approval for the NSCLC indication on 4 September 2020, based [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[5137],"tags":[],"class_list":["post-46126","post","type-post","status-publish","format-standard","hentry","category-world-news"],"_links":{"self":[{"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/posts\/46126","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/comments?post=46126"}],"version-history":[{"count":1,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/posts\/46126\/revisions"}],"predecessor-version":[{"id":46286,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/posts\/46126\/revisions\/46286"}],"wp:attachment":[{"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/media?parent=46126"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/categories?post=46126"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/tags?post=46126"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}